| Literature DB >> 31285272 |
Xinxing Zhu1, Duchu Chen2,3, Yanli Liu4, Jinjin Yu5, Liang Qiao4, Shuibin Lin6, Demeng Chen6, Genshen Zhong7, Xifeng Lu8, Yize Wang2, Jieqi Wen2, Xinqi Zhong9, Yizhou Jiang10.
Abstract
The long noncoding RNA HOXA-AS3 has recently been reported to act as a critical regulator in inflammation-linked lung adenocarcinoma. However, the roles of HOXA-AS3 in endothelium inflammation and related vascular disorders remain poorly defined. In the current study, we identified HOXA-AS3 to be a critical activator to promote NF-κB-mediated endothelium inflammation. HOXA-AS3, a chromatin-associated regulator which colocalizes with NF-κB at specific gene promoters, was found to interact with NF-κB and positively regulate its activity through control of the expression of the NF-κB inhibitor protein IκBα and the acetylation status at the K310 site of p65. More importantly, clinicopathological analysis showed that HOXA-AS3 expression has a significant positive correlation with atherosclerosis. Thus, we conclude that HOXA-AS3 may serve as a crucial biomarker for the clinical diagnosis of atherosclerosis, as well as a promising therapeutic target for the treatment of multiple inflammatory vascular diseases. In addition, this study suggests the functional importance of HOXA-AS3 in the regulation of inflammatory disorders.Entities:
Keywords: HOXA-AS3; NF-κB; acetylation; atherosclerosis; endothelium inflammation
Mesh:
Substances:
Year: 2019 PMID: 31285272 PMCID: PMC6751633 DOI: 10.1128/MCB.00139-19
Source DB: PubMed Journal: Mol Cell Biol ISSN: 0270-7306 Impact factor: 4.272